考慮區域性差異之多區域藥物臨床試驗之評估與設計 Design and Evaluation of Multi-regional Clinical Trials With Heterogeneous Treatment Effect Across Regions Chi-Tian Chen Advisor.

Slides:



Advertisements
Similar presentations
Bridging Studies Global Development W. Joe Shih Biostatistics Dept UMDNJ-School of Public Health Sept. 29, 2006 FDA/Industry Conference, Washington D.C.
Advertisements

Sample size estimation
A Flexible Two Stage Design in Active Control Non-inferiority Trials Gang Chen, Yong-Cheng Wang, and George Chi † Division of Biometrics I, CDER, FDA Qing.
ICH E-5 Overview and Current Topics Mamoru Narukawa.
4 th Kitasato-Harvard Symposium: Summary and Conclusions Stephen Lagakos Harvard School of Public Health.
Many Important Issues Covered Current status of ICH E5 and implementation in individual Asian countries Implementation at a regional level (EU) and practical.
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Statistical Issues in Contraceptive Trials
Topic 6: Introduction to Hypothesis Testing
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
Journal Club Alcohol and Health: Current Evidence July-August 2006.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Statistical considerations for a multi-regional trial Hiroyuki Uesaka, Ph. D October 28, 2003 Kitasato University-Harvard School of Public Health Symposium.
BS704 Class 7 Hypothesis Testing Procedures
Dejun Tang, Novartis Pharma, China PSI Webinar July 16, 2015 Challenges and Opportunities on Multi-regional Clinical Trials Including Asian Countries.
Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.
RANDOMIZED CLINICAL TRIALS. What is a randomized clinical trial?  Scientific investigations: examine and evaluate the safety and efficacy of new drugs.
Sample Size Determination Ziad Taib March 7, 2014.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
1 ACI Life Sciences Mergers & Acquisitions – March 12, 2009 ASENT INTERNATIONAL SYMPOSIUM ~ Acceptability of Foreign Data~ February 26, 2011 February 26,
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Dr Mohammad Hossein Fallahzade Determining the Size of a Sample In the name of God.
International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.
Norisuke Kawai Clinical Statistics, Pfizer Japan Inc.
Stefan Franzén Introduction to clinical trials.
Sampling Techniques LEARNING OBJECTIVES : After studying this module, participants will be able to : 1. Identify and define the population to be studied.
Significance of Extrapolation of Foreign Clinical Data to Asian Countries Masahiro Takeuchi Div. of Biostatistics Kitasato University Graduate School The.
Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.
Maximum Likelihood Estimator of Proportion Let {s 1,s 2,…,s n } be a set of independent outcomes from a Bernoulli experiment with unknown probability.
1 © 2008 Brooks/Cole, a division of Thomson Learning, Inc. Chapter 12 The Analysis of Categorical Data and Goodness-of-Fit Tests.
Impact of E9 Addendum to Industry
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Therapeutic Equivalence & Active Control Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.
All-or-None procedure: An outline Nanayaw Gyadu-Ankama Shoubhik Mondal Steven Cheng.
The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
PH 401: Meta-analysis Eunice Pyon, PharmD (718) , HS 506.
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.
1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.
1 Chapter 9 Bridging Studies & Multi-Regional Trials.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
MPS/MSc in StatisticsAdaptive & Bayesian - Lect 41 Lecture 4 Sample size reviews 4.1A general approach to sample size reviews 4.2Binary data 4.3Normally.
1 Chapter 9 Bridging Studies & Multi-Regional Trials.
Chapter 6 Conducting & Reading Research Baumgartner et al Chapter 6 Selection of Research Participants: Sampling Procedures.
European Patients’ Academy on Therapeutic Innovation The Purpose and Fundamentals of Statistics in Clinical Trials.
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
| 1 Application of a Bayesian strategy for monitoring multiple outcomes in early oncology clinical trials Application of a Bayesian strategy for monitoring.
Chapter 9: Means and Proportions as Random Variables 9.1 Understanding dissimilarity among samples 9.2 Sampling distributions for sample proportions 9.3.
European Obesity Academy Assmannshausen 2016 Statistics; power calculation and randomization Johan Bring Statisticon AB.
My Experiences as an FDA Statistician
Recent Evolution of New Drug Review and Approval System in Korea
Quintiles East Asia Ltd Singapore
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
ICH E17 General Principles for Planning and Design of MRCTs
Improving Adverse Drug Reaction Information in Product Labels
Deputy Director, Division of Biostatistics No Conflict of Interest
Introduction to GCP and Ethical considerations in clinical trials
Elaine M Pascoe, Darsy Darssan, Liza A Vergara
Pilot Studies: What we need to know
راهنماي اختصاصي اخلاق در كارآزمايي هاي باليني
Covering Principle to Address Multiplicity in Hypothesis Testing
Handling Missing Not at Random Data for Safety Endpoint in the Multiple Dose Titration Clinical Pharmacology Trial Li Fan*, Tian Zhao, Patrick Larson Merck.
Optimal Basket Designs for Efficacy Screening with Cherry-Picking
The 3rd Stat4Onc Annual Symposium
Hui Quan, Yi Xu, Yixin Chen, Lei Gao and Xun Chen Sanofi June 28, 2019
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Effect
Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.
Evidence Based Diagnosis
Aparna Raychaudhuri, Ph. D
Presentation transcript:

考慮區域性差異之多區域藥物臨床試驗之評估與設計 Design and Evaluation of Multi-regional Clinical Trials With Heterogeneous Treatment Effect Across Regions Chi-Tian Chen Advisor : Chin-Fu Hsiao, Ph.D. Yun-Ming Pong, Ph.D. Abstrat To speed up drug development to allow faster access to medicines for patients globally, conducting multi- regional clinical trials incorporating subjects from many countries around the world under the same protocol may be desired. Several statistical methods have been purposed for the design and evaluation of multi-regional clinical trials. However, in most of recent approaches for sample size determination in multi-regional clinical trials, a common treatment effect of the primary endpoint (continuous or binary endpoint) across regions is usually assumed. In practice, it might be expected that there is a difference in treatment effect due to regional difference (e.g., ethnic difference). For continuous endpoint, a random effect model for heterogeneous treatment effect across regions is proposed for the design and evaluation of multi-regional clinical trials in this dissertation. For binary endpoint, a power-function distribution is used to describe heterogeneous treatment effect across regions for the design and evaluation of multi-regional clinical trials. We also address consideration on the determination of the number of subjects in a specific region to establish the consistency of treatment effects between the specific region and the entire group. Material and result 1. Continuous case For continuous endpoints, a random effect model is used to describe the heterogeneity of the treatment results from the participated regions in a multi- regional clinical trial. An estimate of the overall treatment difference, the formulas for the sample size determination, and a test statistic for testing nonpositive effect between a test product and a placebo control are included. 2. Binary case In clinical trials, a binary study endpoint such as response rate is often considered as the primary endpoint for evaluation of the efficacy of a test treatment. In this chapter, we will establish statistical methodology by considering heterogeneity among regions in a multi-regional clinical trial for binary endpoint. A power-function distribution will be used to describe the heterogeneity among regions. 3. Examples In order to illustrate our approaches, suppose that a multi-regional clinical trial will be conducted in 3 regions (for example, Taiwan, European Union (EU), and United States (USA)). let p 1 be the proportion of patients in the smallest region, p 2 the proportion of patients in the second smallest region, and p 3 the proportion of patients in the largest region. For continuous case, the first line in Table 2.1 corresponds to a design with (p 1, p 2, p 3 )=(0.1, 0.1, 0.8), (θ 1, θ 2, θ 3 )=(10, 15, 15), and τ 2 =1. In this case, the total sample size required per group in the multi-regional clinical trial is 64, and the assurance probability for the first region is This indicates that the sample size for the smallest region has to be around 10% of the overall sample size to maintain the assurance probability at 80% level. For binary case, the first panel in Table 3.1 corresponds to a design with (r 1 T, r 2 T, r 3 T )=(35%,40%,40%), r 1 C = r 2 C = r 3 C =20%, and p 1 = p 2 < p 3. That is, (π 1, π 2, π 3 )=(15%, 20%, 20%). When (p 1, p 2, p 3 )=(0.1, 0.1, 0.8), the total sample size required per group in the multi-regional clinical trial is 179, and the assurance probability for the first region is As seen in Table 3.1, the sample size for the smallest region has to be around 20% of the overall sample size to maintain the assurance probability at 80% level. Reference 1.Chow, S. C., Shao, J., and Wang, H. (2002). A note on sample size calculation for mean comparisons based on noncentral t-statistics. Journal of Biopharmaceutical Statistics 12(4): 441– Caraco Y. (2004). Genes and the response to drugs. The New England Journal of Medicine 351(27):2867– DerSimonia R. and Laird N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7: Eichebaum M., Spannbrucker N., Steincke B., et al. (1979). Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology 16:183–7. 5.Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). Journal Clinical Oncology 21: Hartung J. (1999). An alternative method for meta-analysis. Biometrical Journal 41(8): Hung H. M. J., Wang S. J., O’Neill. R. T. (2010). Consideration of regional difference in design and analysis of multi-regional trials. Pharmaceutical Statistics 9: International Conference on Harmonisation. (1998). Tripartite guidance E5, Ethnic factors in the acceptability of foreign data. Federal Register 83:31790– International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (2006). Q&A for the ICH E5 Guldeline on Ethnic Factors in the Acceptability of Foreign Data. Available at: pdf pdf 10.Kawai, N., Stein, C., Komiyama O., and Li, Y. (2008). An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Information Journal 42: Ko F. S., Tsou H. H., Liu J. P., Hsiao C. F. (2010). Sample size determination for a specific region in a multi-regional trial. Journal of Biopharmaceutical Statistics 20: Mahgoab A., Idle J. R., Drig L. G., et al. (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584– Ministry of Health, Labor, and Welfare of Japan. (2007). Basic Principles on Global Clinical Trials. Tokyo: MHLW. 14.Quan, H., Zhao, P. L., Zhang, J., Roessner, M., and Aizawa, K. (2009). Sample size considerations for Japanese patients in a multi- regional trial based on MHLW guidance. Pharmaceutical Statistics 9: Uesaka, H. (2009) Sample size allocation to regions in a multiregional trial. Journal of Biopharmaceutical Statistics 19: Whitehead A. (2002). Meta-analysis of Controlled Clinical Trials. New York: Wiley.